6. AscentX Medical raises $1m for GERD treatment
AscentX Medical said in a regulatory filing that it raised $1.2 million of a hoped-for $2.2 million goal for its G125 treatment for gastro-esophageal reflux disease. G123 is a permanent, injectable bulking agent designed to endoscopically cure GERD by restoring the lower esophageal sphincter’s pressure, according to the San Diego-based company’s website.